Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma
出版年份 2021 全文链接
标题
Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma
作者
关键词
-
出版物
Cancers
Volume 13, Issue 6, Pages 1383
出版商
MDPI AG
发表日期
2021-03-18
DOI
10.3390/cancers13061383
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes
- (2020) Cindy Patinote et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Optimizing Oncolytic Viral Design to Enhance Antitumor Efficacy: Progress and Challenges
- (2020) Shyambabu Chaurasiya et al. Cancers
- High response rates for T-VEC in early metastatic melanoma (stage IIIB/C-IVM1a)
- (2019) Viola Franke et al. INTERNATIONAL JOURNAL OF CANCER
- Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience
- (2019) Raphael J. Louie et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- Talimogene laherparepvec: review of its mechanism of action and clinical efficacy and safety
- (2019) Steven S Raman et al. Immunotherapy
- Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma
- (2019) Robert H. I. Andtbacka et al. Journal for ImmunoTherapy of Cancer
- Intratumoral Immunotherapy—Update 2019
- (2019) Omid Hamid et al. ONCOLOGIST
- Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
- (2018) Jason Chesney et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- (2018) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- 1246PDTalimogene laherparepvec (T-VEC) treatment increases intratumoral effector T-cell and natural killer (NK) cell density in noninjected tumors in patients (pts) with stage IIIB–IVM1c melanoma: Evidence for systemic effects in a phase II, single-arm study
- (2018) H Gogas et al. ANNALS OF ONCOLOGY
- Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience
- (2018) Matthew C. Perez et al. ANNALS OF SURGICAL ONCOLOGY
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
- (2017) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial
- (2016) Robert H. I. Andtbacka et al. ANNALS OF SURGICAL ONCOLOGY
- Oncolytic virus therapy: A new era of cancer treatment at dawn
- (2016) Hiroshi Fukuhara et al. CANCER SCIENCE
- Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma
- (2016) Igor Puzanov et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial
- (2016) Kevin Harrington et al. OncoTargets and Therapy
- Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
- (2016) P.-L. Chen et al. Cancer Discovery
- Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy
- (2015) F. J. Kohlhapp et al. CLINICAL CANCER RESEARCH
- Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma
- (2015) Douglas B Johnson et al. Immunotherapy
- Immune Checkpoint Blockade in Cancer Therapy
- (2015) Michael A. Postow et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
- (2015) Alexander M M Eggermont et al. LANCET ONCOLOGY
- Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma
- (2014) John F. Thompson et al. ANNALS OF SURGICAL ONCOLOGY
- In-transit Melanoma Metastases: Incidence, Prognosis, and the Role of Lymphadenectomy
- (2014) Rebecca L. Read et al. ANNALS OF SURGICAL ONCOLOGY
- Cancer statistics, 2014
- (2014) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Intralesional therapy with PV-10 (Rose Bengal) for in-transit melanoma
- (2014) Merrick I. Ross JOURNAL OF SURGICAL ONCOLOGY
- Topical pharmacotherapy for skin cancer
- (2014) Giuseppe Micali et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- CTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy
- (2014) Christine E Engeland et al. MOLECULAR THERAPY
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
- (2014) D. Zamarin et al. Science Translational Medicine
- Treatment of metastatic melanoma with electrochemotherapy
- (2013) Luca G. Campana et al. JOURNAL OF SURGICAL ONCOLOGY
- Oncolytic virotherapy
- (2012) Stephen J Russell et al. NATURE BIOTECHNOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Natural Innate and Adaptive Immunity to Cancer
- (2011) Matthew D. Vesely et al. Annual Review of Immunology
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- High response rate after intratumoral treatment with interleukin-2
- (2010) Benjamin Weide et al. CANCER
- Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma
- (2009) Howard L. Kaufman et al. ANNALS OF SURGICAL ONCOLOGY
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma
- (2009) Neil N. Senzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Contrasting roles for all-trans retinoic acid in TGF-β–mediated induction ofFoxp3andIl10genes in developing regulatory T cells
- (2009) Craig L. Maynard et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Oncolytic virotherapy: Molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses
- (2008) Z. Sheng Guo et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- NK cells and cancer immunosurveillance
- (2008) I Waldhauer et al. ONCOGENE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now